Novartis provides funding to US nonprofit healthcare or healthcare-related organizations to support a variety of healthcare-related activities or events that align with our goal of improving public health.

We will evaluate sponsorship and membership requests only from US organizations that have non-profit status [501(c)3, 501(c)4, or 501(c)6] in the following categories such as:

Medical Patient Advocacy
  • Sponsoring medical congresses/research meetings
  • Corporate membership dues
  • Closed meetings with multi-stakeholders
  • Fundraising events/recognition ceremonies
  • Membership dues on behalf of Novartis
  • Community outreach programs (such as disease awareness & education)
  • Walks, runs, bike rides
  • Policy initiatives
  • Symposia/roundtable meetings
  • Fundraising events/award ceremonies

Sponsorship and membership requests are required to have tangible benefits.

To be considered, a complete application package should be submitted via the online portal at least 60 calendar days prior to the event date. If the completed application package is not received at least 60 days prior to the event date, the request may be denied.

Required documents for submitting a Sponsorship or Membership request

  • Letter of request
  • Overall program budget
  • List of any benefits associated with the Sponsorship or Membership
  • Current W9 (signed and dated)

Following are examples of submissions that will not be accepted for a Sponsorship or Membership request

  • Requests related to Novartis products, in particular marketing and sales activities (i.e. promotional exhibit or booth space at scientific exchange congresses, promotional product theater, etc.)
  • Contractual service agreements or fee-for-service arrangements
  • Initiatives focused solely on raising awareness of Novartis-specific clinical trials

Novartis will receive and review sponsorship and membership requests in the following areas. Please note that these areas are subject to change and the funding availability may vary.

Medical Sponsorships and Memberships

  • Allergy
  • Cardiovascular – Hyperlipidemia
  • Cardiovascular - ASCVD
  • Dermatology
  • Multiple Sclerosis
  • Nephrology
  • Rheumatology
  • Other

Patient Advocacy Sponsorships and Memberships

  • Arthritis
  • Asthma/Allergy
  • Cardiovascular/Heart Failure
  • Dermatology
  • Multiple Sclerosis
  • Non-Therapeutic Area Specific* (Excludes Philanthropic requests)
  • Neuroscience
  • Ophthalmology
  • Transplant

Novartis will receive and review sponsorship and membership requests in the following areas. Please note that these areas are subject to change and the funding availability may vary.

Medical Sponsorships and Memberships

  • Oncology/Hematology
  • Neuroendocrine Tumors/Prostate Cancer

Patient Advocacy Sponsorships and Memberships

  • Breast Cancer
  • Cell and Gene Therapies
  • Gastrointestinal Stromal Tumors (GIST)
  • General Education for Patients with Cancer
  • Immune Thrombocytopenia (ITP)
  • Iron Overload
    • Thalassemia
    • Myelodysplastic Syndromes
  • Leukemia/Lymphoma
  • Lung Cancer
  • Melanoma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Rare Diseases 
    • Acromegaly
    • Tuberous Sclerosis Complex
    • General Education for Patients with Rare Diseases
  • Renal Cell Cancer
  • Sickle Cell Disease
  • Soft Tissue Sarcoma

Disclaimer

Please do not consider any request approved until you have received written documentation from Novartis that your application has been approved for funding and all of the required paperwork, including a counter-signed original Letter of Agreement, has been received by you. Any expenses incurred prior to receiving written support of the program by Novartis are taken at your own risk.

Previous support by Novartis does NOT guarantee future support as each request is evaluated on individual merit. If you have any questions, please contact a member of the US Professional Medical Education or Patient Advocacy Teams. Please do NOT contact your sales representative, regional scientific director, or marketing personnel regarding the status of a request.

Novartis will review each submission in a timely manner. Your prompt response to requests for any additional information is critical to this process and appreciated.

Novartis is aware of the growing need for education and support for the medical and patient/caregiver communities. Many more requests are received than can be funded and we regret that we cannot accommodate every request. However, your submission will receive a fair and thorough review. In return, please take time to consider how your program fits within the therapeutic areas of interest for Novartis and the established regulations, laws and guidelines before submitting a request.